202 related articles for article (PubMed ID: 18568550)
21. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.
Andrade RS; Heron DE; Degirmenci B; Filho PA; Branstetter BF; Seethala RR; Ferris RL; Avril N
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1315-22. PubMed ID: 16750327
[TBL] [Abstract][Full Text] [Related]
22. What does PET imaging add to conventional staging of head and neck cancer patients?
Pohar S; Brown R; Newman N; Koniarczyk M; Hsu J; Feiglin D
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):383-7. PubMed ID: 17379443
[TBL] [Abstract][Full Text] [Related]
23. ¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography in malignancies of the thyroid and in head and neck squamous cell carcinoma: a review of the literature.
Lauridsen JK; Rohde M; Thomassen A
PET Clin; 2015 Jan; 10(1):75-88. PubMed ID: 25455881
[TBL] [Abstract][Full Text] [Related]
24. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck.
Zimmer LA; Branstetter BF; Nayak JV; Johnson JT
Laryngoscope; 2005 Nov; 115(11):2029-34. PubMed ID: 16319618
[TBL] [Abstract][Full Text] [Related]
25. The potential role of non-FDG-PET in the management of head and neck cancer.
Heuveling DA; de Bree R; van Dongen GA
Oral Oncol; 2011 Jan; 47(1):2-7. PubMed ID: 21109481
[TBL] [Abstract][Full Text] [Related]
26. [18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality.
de Souza JA; Cohen EE
J Clin Oncol; 2010 Oct; 28(28):e516; author reply e517. PubMed ID: 20606097
[No Abstract] [Full Text] [Related]
27. Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma.
Périé S; Hugentobler A; Susini B; Balogova S; Grahek D; Kerrou K; Montravers F; Chater PE; St Guily JL; Talbot JN
Otolaryngol Head Neck Surg; 2007 Oct; 137(4):647-53. PubMed ID: 17903585
[TBL] [Abstract][Full Text] [Related]
28. Prospective comparison of
Lopez R; Gantet P; Salabert AS; Julian A; Hitzel A; Herbault-Barres B; Fontan C; Alshehri S; Payoux P
J Craniomaxillofac Surg; 2017 Sep; 45(9):1486-1492. PubMed ID: 28764952
[TBL] [Abstract][Full Text] [Related]
29. Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.
Kitajima K; Suenaga Y; Sugimura K
Jpn J Radiol; 2015 Dec; 33(12):776-89. PubMed ID: 26507982
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment positron emission tomography with [18F]fluorodeoxyglucose for head and neck squamous cancer.
Paleri V; Zammit-Maempel I
J Clin Oncol; 2010 Oct; 28(28):e515. PubMed ID: 20606098
[No Abstract] [Full Text] [Related]
31. Correlation between pretreatment FDG-PET biological target volume and location of T-site failure after definitive radiation therapy for head and neck cancers.
Sand HM; Brunø AH; Andersen LJ; Carl J
Acta Oncol; 2015; 54(9):1682-5. PubMed ID: 26398889
[No Abstract] [Full Text] [Related]
32. FDG-PET in radiotherapy treatment planning of advanced head and neck cancer--a prospective clinical analysis.
Dietl B; Marienhagen J; Kühnel T; Schaefer C; Kölbl O
Auris Nasus Larynx; 2006 Sep; 33(3):303-9. PubMed ID: 16497462
[TBL] [Abstract][Full Text] [Related]
33. Comparison of CT- and FDG-PET-defined GT: in regard to Paulino et al. (Int J Radiat Oncol Biol Phys 2005;61:1385-1392).
Gregoire V; Daisne JF; Geets X
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):308-9; author reply 309. PubMed ID: 16111601
[No Abstract] [Full Text] [Related]
34. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.
Heron DE; Ferris RL; Karamouzis M; Andrade RS; Deeb EL; Burton S; Gooding WE; Branstetter BF; Mountz JM; Johnson JT; Argiris A; Grandis JR; Lai SY
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1493-500. PubMed ID: 19464819
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma.
Connell CA; Corry J; Milner AD; Hogg A; Hicks RJ; Rischin D; Peters LJ
Head Neck; 2007 Nov; 29(11):986-95. PubMed ID: 17563906
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
37. Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report.
Heron DE; Andrade RS; Flickinger J; Johnson J; Agarwala SS; Wu A; Kalnicki S; Avril N
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1419-24. PubMed ID: 15590173
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
Kim SY; Kim JS; Yi JS; Lee JH; Choi SH; Nam SY; Cho KJ; Lee SW; Kim SB; Roh JL
Ann Surg Oncol; 2011 Sep; 18(9):2579-84. PubMed ID: 21409485
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer.
Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773
[TBL] [Abstract][Full Text] [Related]
40. Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial.
Senft A; de Bree R; Hoekstra OS; Kuik DJ; Golding RP; Oyen WJ; Pruim J; van den Hoogen FJ; Roodenburg JL; Leemans CR
Radiother Oncol; 2008 May; 87(2):221-9. PubMed ID: 18410977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
